Skip to main content

Table 2 Treatment efficacy of KRAS mutant NSCLC received first-line treatment

From: A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice

KRAS mutant NSCLC

ORR

DCR

Chemotherapy

Immunotherapy

P value

Chemotherapy

Immunotherapy

P value

Overall

30.43% (36/165)

44.00%

0.893

80.00%

96.00%

0.439

KRAS mutant subtypes

 G12C

29.63%

54.17%

0.667

81.48%

95.83%

0.924

 non-G12C

30.12%

34.62%

0.654

78.31%

92.31%

0.679

PD-L1 expression

  < 1%

15.38%

20.00%

0.686

84.62%

100.00%

0.911

  ≥ 1%

48.28%

47.50%

0.979

89.66%

95.00%

0.724